That has led some on Wall Street to anticipate a looming threat for food and beverage companies should consumers cut back on salty snacks, though others have pushed back, saying the outlook isn't so dire
The company states that interim results from the ongoing phase 1b study assessing multiple ascending doses of GUBamy are expected during the first half of 2025 [117]
difficulty losing weight even with diet and exercise
Clinical studies Compared with the considerable amount of pre-clinical and mechanistic research reported above, we identified few clinical studies of GLP-1RAs for substance-use disorders (Table 2): three for alcohol 111,112,113 , one for cannabis 114 , two for cocaine 115,116 and two for nicotine 117,118 , while no article about opiates or amphetamines was retrieved
This is the initiation phase
Current medical research and opinion